Stereotactic radiotherapy for oligometastatic cancer

Patients diagnosed with metastatic cancer are living longer due to advances in both systemic anti-cancer therapies and radiotherapy. Metastases from primary tumours cause morbidity and it is estimated that metastases are responsible for approximately 90% of all cancer deaths.

The concept of oligometastatic disease (OMD) was first proposed in a seminal paper in 1995 by Hellman and Weichselbum. They described an intermediate state between localised cancer and widespread metastatic disease.

The content on this page is provided by the individuals concerned and does not represent the views or opinions of RAD Magazine.

Stay up to date with
RAD Magazine

Sign up for our newsletter.

We care about your data. Read our privacy policy.